在接受神经干预手术的患者中,基因型导向抗血小板治疗和临床结果
Kayla R Tunehag1, Ashton F Pearce1, Layna P Fox1
1Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Clinical and translational science
|January 17, 2025
概括
CYP2C19基因型检测可以指导抗血小板治疗选择,以预防中风. 患有特定CYP2C19基因变异的患者可能会有更糟糕的结局与克洛皮多格雷尔,这表明需要基因型导向的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药物基因组学 药物基因组学
- 心血管医学 心血管医学
背景情况:
- 双重抗血小板治疗 (P2Y12抑制剂和阿司匹林) 是神经血管疾病的标准.
- 克洛皮多格勒是一种常见的P2Y12抑制剂,但其有效性在具有CYP2C19无功能等位基因的个体中降低.
- CYP2C19基因型影响了克洛皮多格雷尔的活性代谢物形成,影响了血小板抑制.
研究的目的:
- 在神经血管疾病中审查CYP2C19基因型引导抗血小板治疗的证据和指导方针.
- 在神经干预手术中评估与CYP2C19基因型和克洛皮多格雷尔相关的临床结果.
- 识别知识缺口和该领域未来的研究方向.
主要方法:
- 文献审查和现有证据的综合.
- 对CYP2C19基因型导向治疗的指南建议的分析.
- 临床结果的评估来自神经干预程序的数据.
主要成果:
- 无功能的CYP2C19基因基因与克洛皮多格雷尔治疗的神经血管患者的治疗结果较差有关.
- 基因型导向疗法在心血管皮肤冠状动脉干预中显示出改善的结果.
- 在神经干预程序中,基因型导向治疗的证据仍在发展.
结论:
- CYP2C19基因型显著影响神经血管疾病患者的克洛皮多格雷尔反应.
- 实施基因型引导的抗血小板治疗可以优化治疗并减少不良事件.
- 需要进一步的研究来澄清基因型导向策略在神经干预设置中的实用性和影响.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
464
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
464
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
450
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
450
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
133
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
133